A Phase I, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2017
At a glance
- Drugs SB 913 (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors Sangamo Therapeutics
- 21 Apr 2017 Status changed from not yet recruiting to recruiting.
- 31 Jan 2017 Planned initiation date changed from 1 Jan 2017 to 1 Apr 2017.
- 11 Jan 2017 According to a Sangamo BioSciences media release, data from this study is expected in late 2017 or early 2018.